


# EVALUATION OF THE REAL INFUSION TIME OF INTRAVENOUS IMMUNOGLOBULIN AND **INFLUENTIAL FACTORS IN ROUTINE CLINICAL PRACTICE ANALYSIS**

<u>C.Alonso-Martínez<sup>1</sup></u>, E. Serramontmany-Morante<sup>1</sup>, A. Roig-Izquierdos<sup>2</sup>, E. Lozano-Ortin<sup>1</sup>, M. Garau-Gomila<sup>1</sup>, L. Betriu-Sebastia<sup>1</sup>, J.B. Montoro-Ronsano<sup>1</sup> <sup>1</sup>Pharmacy Service, Nursing<sup>2</sup>, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

## Background

Intravenous immunoglobulin (IVIG) is the standard of care for humoral immunodeficiencies (HID) and several systemic autoimmune diseases. Its chronic administration represents an important economic and logistical impact.



To asses the real time of infusion of IVIG compared to the established maximums and to analyse which factors could affect it, in order to find out if the infusion rate could be higher.

Purpose

### Material and Methods

### **OBSERVATIONAL, AMBISPECTIVE STUDY**

✓ **Population:** patients chronically receiving IVIG ,day tertiary hospital

- ✓ **Study period:** December 2016 March 2017
- **Variables registred** (from medical records and nursing software)
  - **Biodemographic data**: sex, age, weight
  - Clinical data: primary diagnosis, dose, frequency of administration
  - Infusion and premedication times

### ✓ Primary endpoint

Infusion time expressed as mean and standard deviation(SD) for each commercial preparation.

#### Also analyzed $\checkmark$

Influence of demographic covariates, IVIg dose, commercial preparation and the need and type of premedication (ANOVA-test performed with Stata<sup>®</sup>)

Results						
Population		Diagnosis		Comercial	Mean and SD of	Total of
Number of patients	175	Humoral immunodeficiencies	69 (39.4%)	preparation <b>EXECUTE</b>	infusion rates	patients
Mean age (years)	55 (20-91)	Neurological disease	89 (50.9%)			****
Men	49 %	Systemic autoimmune disease	17 (9.7%)	Intratec®	9.14 g/h SD 0.98 g/h	n=3
The dose administered, need of premedication and commercial				Octagamocta®	8.48 g/h SD 1.81g/h	n=25
preparation had an impact on the time of infusion; however, it was not affected by sex, weight or age.				Privigen®	8.39 g/h SD 2.30g/h	n=84
<ul> <li>All preparations were infused at a lower rate (p &lt;0.05) than the maximum set in the technical sheet.</li> <li>Premedication was necessary in 72 patients (41%) being oral acetaminophen the most commonly used. However, premedication combinations were also effective (31 patients,18%) being acetaminophen + dexchlorpheniramine (11 patients) the most used.</li> </ul>				Flebogamma- Plangamma5%®	7.33 g/h SD 1.76 g/h	n=36
				Flebogamma10%®	7.61 g/h SD 1.54 g/h	n=16
				Kiovig®	7.30 g/h SD 2.60g/h	n=6
				Gammagard®	6.44 g/h SD 2.08 g/h	n=5



Administration of IVIG is performed at an **infusion rate that is below** the established maximums.

Many patients **need premedication** to avoid infusion reactions

**Increasing the rate** of IVIG administration **should be considered** for those patients with good tolerance, saving time and money invested in day hospital.





Generalitat de Catalunya Departament de Salut

Institut Català de la Salut